Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Agreement between FGFR2 immunohistochemistry assays and fluorescence in situ hybridization (FISH) in metastatic gastric cancer: A comparison study.
Authors
Grigory A. Raskin
Dr. Berezin Medical Institute, Saint Petersburg, Russian Federation;
Grigory A. Raskin , Marina S. Mukhina , Elena D. Kravtsova , Sergei Tjulandin , Ilya Tsimafeyeu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Diagnostics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 301)
DOI
10.1200/JCO.2023.41.4_suppl.301
Abstract #
301
Poster Bd #
B20
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).
First Author: Seung Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Expression of claudin 18.2 in peritoneal metastasis (PM) of gastric cancer.
First Author: Akira Saito
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.
First Author: Ilya Tsimafeyeu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinicopathological features of HER2-low expressed advanced gastric cancers.
First Author: Izuma Nakayama